Evaluation of the Spanish population coverage of a prospective HLA haplobank of induced pluripotent stem cells

Other authors

Institut Català de la Salut

[Álvarez-Palomo B, Querol S] Banc de Sang i Teixits, Barcelona, Spain. Grup d’Enginyeria tissular musculoesquelètica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [García-Martinez I] Banc de Sang i Teixits, Barcelona, Spain. [Gayoso J] Organización Nacional de Trasplantes, Ministerio de Sanidad, Madrid, Spain. [Raya A, Veiga A] Programa de Medicina Regenerativa, Institut d’Investigació Biomèdica de Bellvitge. IDIBELL, Hospital Duran i Reynals, L’Hospitalet de Llobregat, Barcelona, Spain. [Abad ML] Axencia Galega de Sangue, Órganos e Tecidos, Santiago de Compostela, Spain. [Vidal F] Banc de Sang i Teixits, Barcelona, Spain. Grup de Medicina Transfusional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2021-11-29T08:28:40Z

2021-11-29T08:28:40Z

2021-04-13



Abstract

Haplobank; Homozigot; Cèl·lules mare pluripotents induïdes


Haplobank; Homocigoto; Células madre pluripotentes inducidas


Haplobank; Homozygous; Induced pluripotent stem cells


Background iPSC (induced pluripotent stem cells) banks of iPSC lines with homozygous HLA (human leukocyte antigen) haplotypes (haplobanks) are proposed as an affordable and off-the-shelf approach to allogeneic transplantation of iPSC derived cell therapies. Cord blood banks offer an extensive source of HLA-typed cells suitable for reprogramming to iPSC. Several initiatives worldwide have been undertaken to create national and international iPSC haplobanks that match a significant part of a population. Methods To create an iPSC haplobank that serves the Spanish population (IPS-PANIA), we have searched the Spanish Bone Marrow Donor Registry (REDMO) to identify the most frequently estimated haplotypes. From the top ten donors identified, we estimated the population coverage using the criteria of zero mismatches in HLA-A, HLA-B, and HLA-DRB1 with different stringencies: high resolution, low resolution, and beneficial mismatch. Results We have calculated that ten cord blood units from homozygous donors stored at the Spanish cord blood banks can provide HLA-A, HLA-B, and HLA-DRB1 matching for 28.23% of the population. Conclusion We confirm the feasibility of using banked cord blood units to create an iPSC haplobank that will cover a significant percentage of the Spanish and international population for future advanced therapy replacement strategies.


This research was funded by the Spanish Ministry of Science, Innovation and Universities, National Plan for Scientific and Technical Research and Innovation 2013-2016 RETOS COLABORACIÓN Program 2017: exp. RTC-2017-6000-1. 2017-2021.

Document Type

Article


Published version

Language

English

Publisher

BMC

Related items

Stem Cell Research & Therapy;12

https://doi.org/10.1186/s13287-021-02301-0

info:eu-repo/grantAgreement/ES/PE2013-2016/RTC-2017-6000-1

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)